CTLA4-Ig (Abatacept)for Prevention of Abnormal Glucose Tolerance and Diabetes in Relatives At -Risk for Type 1

PHASE2CompletedINTERVENTIONAL
Enrollment

212

Participants

Timeline

Start Date

March 31, 2013

Primary Completion Date

December 14, 2021

Study Completion Date

December 14, 2022

Conditions
Abnormal Glucose ToleranceType 1 Diabetes
Interventions
DRUG

CTLA4-Ig (Abatacept)

Given as 30 minute IV infusion

DRUG

Placebo

Saline given as 30 minute IV infusion

Trial Locations (17)

15213

Children's Hospital of Pittsburgh of UPMC, Pittsburgh

University of Pittsburgh, Pittsburgh

33136

University of Miami School of Medicine, Miami

46202

Indiana University-Riley Hospital for Children, Indianapolis

57931

University of Minnesota, Minneapolis

60637

University of Chicago, Chicago

77030

Baylor College of Medicine, Houston

80262

Barbara Davis Center for Childhood Diabetes, University of Colorado, Denver

94143

University of California - San Francisco, San Francisco

98101

Benaroya Research Institute at Virginia Mason, Seattle

94305-5208

Stanford University Medical Center, Stanford

Unknown

Yale Medical School, New Haven

Columbia University, New York

Vanderbilt University, Nashville

32610-

University of Florida, Gainesville

75390-8858

University of Texas Medical Center at Dallas, Dallas

MSG-1X8

The Hospital for Sick Children, Toronto

Sponsors
All Listed Sponsors
collaborator

Juvenile Diabetes Research Foundation

OTHER

lead

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

NIH